论文部分内容阅读
目的探讨曲美他嗪联合瑞舒伐他汀治疗冠心病合并慢性心力衰竭的临床疗效。方法选取徐州医科大学附属第三医院2015—2016年收治的冠心病合并慢性心力衰竭患者96例,随机分为对照组和观察组,各48例。对照组患者给予常规综合性治疗,观察组患者在对照组基础上给予曲美他嗪联合瑞舒伐他汀治疗,两组患者均持续治疗1个月。比较两组患者临床疗效,治疗前后心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、6 min步行距离(6MWD)、超敏C反应蛋白(hs-CRP)及血脂指标[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)],并观察患者不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者LVEF、LVEDD、LVESD、6MWD、hs-CRP、TC、TG、HDL-C、LDL-C比较,差异无统计学意义(P>0.05);治疗后,观察组患者LVEF、HDL-C高于对照组,LVEDD、LVESD、hs-CRP、TC、TG、LDL-C低于对照组,6MWD长于对照组(P<0.05)。两组患者治疗期间均未出现严重不良反应。结论曲美他嗪联合瑞舒伐他汀治疗冠心病合并慢性心力衰竭的临床疗效确切,可有效改善患者心功能及血脂水平,降低炎性反应,且安全性高。
Objective To investigate the clinical efficacy of trimetazidine combined with rosuvastatin in the treatment of coronary heart disease complicated with chronic heart failure. Methods Ninety-six patients with coronary heart disease and chronic heart failure admitted to the Third Affiliated Hospital of Xuzhou Medical University from 2015 to 2016 were randomly divided into control group and observation group, with 48 cases in each group. Patients in the control group were given routine general treatment. Patients in the observation group were treated with trimetazidine and rosuvastatin on the basis of the control group, and both groups were treated for one month. The clinical curative effect, LVEF, LVEDD and LVESD before and after treatment were compared between the two groups. The 6-minute walking distance (6MWD) (CR) and serum lipids (TC, TG, HDL-C and LDL-C) were determined by ELISA. Observe the occurrence of adverse reactions in patients. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). Before treatment, there was no significant difference in LVEF, LVEDD, LVESD, 6MWD, hs-CRP, TC, TG, HDL-C and LDL-C between the two groups HDL-C was higher than that of the control group. LVEDD, LVESD, hs-CRP, TC, TG and LDL-C were lower than those of the control group and 6MWD was longer than the control group (P <0.05). Two groups of patients during the treatment did not appear serious adverse reactions. Conclusion Trimetazidine combined with rosuvastatin is effective in treating coronary heart disease complicated with chronic heart failure. It can effectively improve the patients’ heart function and blood lipid level, reduce the inflammatory reaction and has high safety.